Sandra N Freiberger
SalvGlandDx - a comprehensive salivary gland neoplasm specific next generation sequencing panel to facilitate diagnosis and identify therapeutic targets.
Freiberger S, Brada M, Fritz C, Höller S, Vogetseder A, Horcic M, Bihl M, Michal M, Lanzer M, Wartenberg M, Borner U, Bode P, Broglie M, Rordorf T, Morand G, Rupp N. SalvGlandDx - a comprehensive salivary gland neoplasm specific next generation sequencing panel to facilitate diagnosis and identify therapeutic targets. Neoplasia 2021; 23:473-487.
18.04.2021SalvGlandDx - a comprehensive salivary gland neoplasm specific next generation sequencing panel to facilitate diagnosis and identify therapeutic targets.
18.04.2021Neoplasia 2021; 23:473-487
Freiberger Sandra N, Brada Muriel, Fritz Christine, Höller Sylvia, Vogetseder Alexander, Horcic Milo, Bihl Michel, Michal Michal, Lanzer Martin, Wartenberg Martin, Borner Urs, Bode Peter K, Broglie Martina A, Rordorf Tamara, Morand Grégoire B, Rupp Niels J
High-grade Salivary Gland Adenocarcinoma Harboring ETV6-NTRK3 Fusion: Defined by Morphology or Molecular Aberration?
Rupp N, Nemes C, Rushing E, Huber G, Freiberger S. High-grade Salivary Gland Adenocarcinoma Harboring ETV6-NTRK3 Fusion: Defined by Morphology or Molecular Aberration?. Head Neck Pathol 2021; 15:1082-1084.
05.02.2021High-grade Salivary Gland Adenocarcinoma Harboring ETV6-NTRK3 Fusion: Defined by Morphology or Molecular Aberration?
05.02.2021Head Neck Pathol 2021; 15:1082-1084
Rupp Niels J, Nemes Constanze, Rushing Elisabeth J, Huber Gerhard, Freiberger Sandra N
Sequential somatic mutations upon secondary anti-HER2 treatment resistance in metastatic ERBB2 mutated extramammary Paget's disease.
Nordmann T, Messerli-Odermatt O, Meier L, Micaletto S, Coppetti T, Nägeli M, Kamarachev J, Kudura K, Freiberger S, Rordorf T, Mangana J, Braun R, Dummer R. Sequential somatic mutations upon secondary anti-HER2 treatment resistance in metastatic ERBB2 mutated extramammary Paget's disease. Oncotarget 2019; 10:6647-6650.
19.11.2019Sequential somatic mutations upon secondary anti-HER2 treatment resistance in metastatic ERBB2 mutated extramammary Paget's disease.
19.11.2019Oncotarget 2019; 10:6647-6650
Nordmann Thierry M, Messerli-Odermatt Olivia, Meier Larissa, Micaletto Sara, Coppetti Thomas, Nägeli Mirjam, Kamarachev Jivko, Kudura Ken, Freiberger Sandra N, Rordorf Tamara, Mangana Joanna, Braun Ralph, Dummer Reinhard